戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ned virologic response at 12 weeks after the cessation of treatment.
2 nograft tumours without recurrence after the cessation of treatment.
3 sion per RECIST v1.1 might prevent premature cessation of treatment.
4 n chronic treatment but reverses slowly upon cessation of treatment.
5 nsgenic mice as evident within 21 days after cessation of treatment.
6 amycin delays tumor recurrence following the cessation of treatment.
7 ncerning for progression of disease prompted cessation of treatment.
8 n effects tend to wane 6-12 months after the cessation of treatment.
9 sed during SIT but started to decrease after cessation of treatment.
10 nist mifepristone, evident 2 weeks after the cessation of treatment.
11 ormance, which was evident 7 weeks after the cessation of treatment.
12   Neutrophil counts returned to normal after cessation of treatment.
13 n was observed, with effects sustained after cessation of treatment.
14 ot understood, its effects persist after the cessation of treatment.
15 siently during treatment but recovered after cessation of treatment.
16 ncreased to control (no treatment) levels on cessation of treatment.
17  growth, however, rapidly advanced following cessation of treatment.
18 ertebral BMD during treatment and 6 mo after cessation of treatment.
19 raft during the rejection observed following cessation of treatment.
20 ist or become enhanced by 48 h following the cessation of treatment.
21  normal and rebound hyperphagia occurring on cessation of treatment.
22 e changes persisted for several months after cessation of treatment.
23 have a sustained clinical response after the cessation of treatment.
24 well tolerated and only occasionally require cessation of treatment.
25  of elevated ALT levels within 3 years after cessation of treatment.
26 uated every 2-4 weeks through 2 months after cessation of treatment.
27 ed ox-LDL levels and then rose following the cessation of treatment.
28  antibiotic exposure and regrow rapidly upon cessation of treatment.
29 itors (ICIs) cause morbidity and necessitate cessation of treatment.
30 onses to the microbiota months following the cessation of treatment.
31 istributions to the entire community, or (4) cessation of treatment.
32 er respiratory tract infections prompted the cessation of treatment.
33 chemotherapy six and twelve months after the cessation of treatment.
34 rneal parameters at least 3 months after the cessation of treatment.
35  followed by a significant improvement after cessation of treatment.
36 an be given in the months to years following cessation of treatment.
37 and a molecular level, which continues after cessation of treatment.
38 s, IM-250 remains effective for a time after cessation of treatment.
39 r treated samples cultured up to 9 days post cessation of treatment.
40 ghtly subnormal almost immediately after the cessation of treatment (50 days of age) with no further
41 dies that evaluated myopic progression after cessation of treatment, a rebound effect was noted.
42                           However, after the cessation of treatment, a recurrence of high relative co
43 ever, the cTEC compartment regenerated after cessation of treatment, accompanied by the restoration o
44  functional adipocytes can be recovered upon cessation of treatment, allowing the study of adipogenes
45 a reversible corneal haze that resolved with cessation of treatment and did not recur in patients res
46 ith oral metronidazole and were evaluated at cessation of treatment and monthly.
47 prognosis, but relapses occur, usually after cessation of treatment and occasionally many years later
48                                              Cessation of treatment and recovery allowed us to monito
49 rapeutic effects were not reversed following cessation of treatment, and IL-13 anti-serum treatment d
50 ing antibiotics but was rapidly cleared upon cessation of treatment, and no relapse was observed in i
51                                              Cessation of treatment at the end of the trial did not r
52 er three months of treatment, and then after cessation of treatment by one and three months, with mea
53                                              Cessation of treatment can be expected to lead to weight
54                                       At the cessation of treatment, corneal nerves in patients with
55        Reinfection commonly occurs following cessation of treatment due to the absence of acquired im
56                             Eight days after cessation of treatment DZP did not have a significant an
57  the emergence of new local adipocytes, upon cessation of treatment, enables the ductal epithelium to
58                          At follow-up, after cessation of treatment for a median of 34 or 35 days, UA
59 nce of autoimmune memory in vitiligo because cessation of treatment frequently led to relapse of dise
60                               However, after cessation of treatment, high titers of IgG anti-dsDNA Ab
61 g hepatitis C virus treatment in 4 and after cessation of treatment in 2.
62  a condition that can persist long after the cessation of treatment in as many as 75% of survivors.
63 risk of secondary transmission of HIV during cessation of treatment in HIV cure-related trials.
64 stored almost to control levels 4 days after cessation of treatment in vivo and fully normalised by 4
65                                              Cessation of treatment led to clinical improvement in al
66                                              Cessation of treatment led to the reappearance of these
67 ndomized trials rarely are utilized to study cessation of treatment, most of what we know about the e
68       Complications severe enough to require cessation of treatment occurred in only 2 patients out o
69 V617F) cells persisted and MPN recurred upon cessation of treatment, suggesting that JAK2 inhibitors
70                                    Following cessation of treatment, T cells and macrophages infiltra
71                      In the first year after cessation of treatment, there was a non-significant incr
72  stasis during the treatment period and upon cessation of treatment, tumours re-grew.
73 prior to randomization and 1 month following cessation of treatment/waiting list.
74                       Median follow-up after cessation of treatment was 32 days (IQR 25-36 days).
75 tment and the waning of resistance following cessation of treatment, we develop two distinct mathemat
76  on bone mass remained up to 12 months after cessation of treatment, while no markers of senescence c
77 GP returned to control level at 3 days after cessation of treatment with either drug but did not retu
78                                              Cessation of treatment with HCG resulted in the return o
79 ll as the time course for its recovery after cessation of treatment with the SSRI sertraline were inv
80 rved between the time to disease flare after cessation of treatment with TNFalpha antagonists and the